| Bioactivity | Livmoniplimab (ABBV-151; ARGX-115) is a potent humanized anti-LRRC32 (GARP)/TGFβ1 monoclonal antibody. Livmoniplimab blocks LRRC32-mediated activation of latent TGFβ1. Livmoniplimab has the potential for the research of cancer[1]. |
| Name | Livmoniplimab |
| CAS | 2412004-88-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li A, et al. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity. J Immunother Cancer. 2022 Sep;10(9):e005433. |